Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Salivary Gland Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 71Bevacizumab 64Carboplatin 56pembrolizumab 46olaparib 32Gemcitabine 29Specimen Handling 27Cyclophosphamide 26liposomal doxorubicin 24Magnetic Resonance Spectroscopy 24Cisplatin 22niraparib 21Taxes 19Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 13Disulfides 13Fulvestrant 12Blood Specimen Collection 11durvalumab 10Oxaliplatin 10mirvetuximab soravtansine 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × 1 year × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡